Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fish bones may fortify Women's bones: new study

NCT ID NCT05066477

Disease control Sponsor: Hofseth Biocare ASA Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether a supplement made from salmon bone powder (CalGo) could help prevent bone loss in perimenopausal women with low bone density. Eighty women aged 50 and older took either the supplement or a placebo for up to 24 months. Researchers measured changes in bone density at the hip, spine, and forearm to see if the supplement slowed bone thinning.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
salmon bone meal (CalGo) with vitamin D3
What this could lead to
If it works, this could provide a natural dietary supplement to help maintain bone density in women at risk for osteoporosis.
What could go wrong
This is a small, completed trial with 80 participants. The supplement may not significantly slow bone loss, and results may not apply to all women.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

80 people

The number who actually took part.

Started

Sep 2021

Finished

Jun 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female gender * ≥ 50 years of age * DXA T-score of \> -2.5 standard deviations, but ≤ -1 (osteopenic range) * Steady state body weight 1 month before study commencement date * No contraindications for intake of the interventional product, including a prior diagnosis of fish allergy. * Familiar with the Norwegian language, both in writing and orally Exclusion Criteria: * A diagnosis of osteoporosis (BMD T-score ≤ -2.5 SD as diagnosed by DXA), or any previously diagnosed fragility fractures on a background of osteoporosis. * Use of drugs known to affect bone metabolism, including: * Glucocorticoids * Thyroid hormones * Hormone replacement therapy taken continuously for a duration of less than 6 months. * Long-term heparin therapy * Anti-convulsive drugs * Long-term proton pump inhibitor treatment * Lithium * Anti-osteoporotic drugs * Cancer therapy * Selective estrogen receptor modulators. * Any disease or medical condition known to affect bone tissue, including neoplasia with or without metastasis, Paget's disease of bone, Osteomalacia, or any other disease deemed relevant by the PI. * Gastrointestinal diseases or disturbances potentially affecting absorption of nutrients, including Crohn's disease and Celiac disease. * Hypersensitivity to ingredients in the interventional product, including fish allergy. * Not willing to participate in the study. * Other reasons that the PI deems it necessary to exclude the subject.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Osteopenia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Bone Diseases, Metabolic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Osteopenia Osteopenia of the elderly

Contacts and locations

Locations

  • Hofseth Biocare ASA

    Ålesund, Møre og Romsdal, 6005, Norway

  • Kristiansund Hospital

    Kristiansund, Møre og Romsdal, 6508, Norway

  • Lovisenberg Diakonale Sykehus

    Oslo, 0456, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.